Viking Therapeutics to Showcase Innovations and Pipeline at Upcoming Healthcare Conferences
- Viking Therapeutics will present at the Leerink Partners Global Healthcare Conference on March 10, 2026, discussing its strategic direction.
- The company is advancing VK2735 in a Phase 3 obesity program and exploring an oral formulation for better accessibility.
- Viking is also developing VK2809 for lipid and metabolic disorders, showing promise in NASH and improving patient outcomes.
Viking Therapeutics Enhances Strategic Presence at Upcoming Healthcare Conferences
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorders, underscores its commitment to innovation and stakeholder engagement by participating in multiple upcoming investor conferences. Notably, Viking will be involved in the Leerink Partners Global Healthcare Conference taking place from March 8-11, 2026, in Miami, Florida. Scheduled for March 10, 2026, from 10:40 to 11:10 a.m. Eastern, a fireside chat will provide insights into Viking's strategic direction and pipeline advancements. The company will also engage in one-on-one meetings during the Jefferies Biotech on the Beach Summit, allowing for deeper discussions with potential investors and collaborators. A live webcast of the Leerink presentation reinforces Viking’s commitment to transparency, with an option for on-demand viewing afterward.
Central to Viking's innovative research efforts is VK2735, a dual agonist targeting GLP-1 and GIP receptors, which is currently progressing through a Phase 3 obesity program consisting of two pivotal trials, VANQUISH-1 and VANQUISH-2. Previous trials have demonstrated VK2735's promising safety profile and significant clinical benefits, positioning it as a potential leader in obesity treatment. Viking is also working on an oral formulation of VK2735, which represents a major innovation in delivering effective obesity therapies to patients in a more accessible manner.
Additionally, Viking is advancing VK2809, an oral small molecule specifically targeting lipid and metabolic disorders. This therapy has seen success in meeting key endpoints during a Phase 2b study for non-alcoholic steatohepatitis (NASH) and fibrosis, with substantial reductions in LDL-C and liver fat compared to placebo observed in Phase 2a trials for non-alcoholic fatty liver disease (NAFLD). The company’s ongoing research into dual amylin and calcitonin receptor agonists (DACRAs) reflects its broader ambition to address obesity and related metabolic conditions, emphasizing Viking's commitment to enhancing therapeutic options and improving patient outcomes.
In addition to its pipeline advancements, Viking's active participation in investor conferences signifies its dedication to fostering relationships within the healthcare community. The focus on transparency through live webcasts and one-on-one meetings enables the company to showcase its innovative approaches and strategic direction, fostering trust among stakeholders and potential investors alike. As Viking Therapeutics continues to make significant strides in the clinical development of novel therapies, its engagement at these conferences highlights the importance of collaboration and dialogue in driving advancements in metabolic and endocrine research.
